Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Literature
1.
Overman MJ, Lonardi S, Leone F, McDermott RS, Morse MA, Wong KYM, et al. Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: update from CheckMate 142. J Clin Oncol. 2017 [cited 2017 Jan 24];35. Available from: http://​meetinglibrary.​asco.​org/​content/​176629-195
2.
Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20:5322–30.CrossRefPubMedPubMedCentral
3.
Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol. 2016;29:1104–12.CrossRefPubMed
4.
Kluger HM, Zito CR, Turcu G, Baine M, Zhang H, Adeniran A, et al. PD-L1 studies across tumor types, its differential expression and predictive value in patients treated with immune checkpoint inhibitors. Clin. Cancer Res. 2017;clincanres.3146.2016.
5.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. J Clin Oncol. 2016;34:suppl; abstr 103.
Metadata
Title
Reply to the Letter by S. Sorscher Regarding “Implications of BRAF Mutations in dMMR Colorectal Cancers”
Authors
R. Cohen, MD
T. André, MD
Publication date
01-10-2017
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 10/2017
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-017-0505-x

Other articles of this Issue 10/2017

Current Treatment Options in Oncology 10/2017 Go to the issue

Gynecologic Cancers (LA Cantrell, Section Editor)

Fertility Sparing Strategies in Patients Affected by Placental Site Trophoblastic Tumor

Gynecologic Cancers (LA Cantrell, Section Editor)

Sentinel Lymph Node Biopsy in Endometrial Cancer: a New Standard of Care?

Genitourinary Cancers (W Oh and M Galsky, Section Editors)

Management of Atypical Renal Cell Carcinomas

Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Rectal Cancer in Asian vs. Western Countries: Why the Variation in Incidence?

Gynecologic Cancers (LA Cantrell, Section Editor)

Immunotherapy in Gynecologic Cancers: Are We There Yet?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits